Hemophilia A And Graves' Focus For Freshly Financed Apitope
This article was originally published in Scrip
Executive Summary
Few will remember Apitope. Those that do will remember it had a good run in 2008, with a series A financing and a licensing deal with Merck Serono for its lead program in multiple sclerosis (MS), and then…near radio silence. Until now. Suddenly that distant MS candidate ATX MS 1467 is Merck Serono's second-to-last remaining hope as a successor to Rebif. And Apitope has two more interesting compounds ready for clinical testing – for hemophilia A and Graves' disease – and the money to fund them with a €12m series B financing announced this week. Scrip's Sukaina Virji caught up with CEO Dr Keith Martin.
You may also be interested in...
Apitope Upbeat After Merck Returns Multiple Sclerosis Candidate
With cladribine battling it out again with regulatory authorities for approval in multiple sclerosis, Merck decides to hand back rights to Apitope's Phase II MS drug candidate.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.